Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: John Bloxom who wrote (252)	2/9/1999 11:14:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 804

For the record, BMY didn't pass on endostatin; ENMD wouldn't license it to BMY. Bullshit. Miljenko, as usual, was correct. The BMY deal with ENMD gave them the right to sublicense anything that was derived from Children's. Bristol-Myers Squibb had right of first refusal with respect to both molecules, and it was well publicized when they passed on endo.

To: John Bloxom who wrote (252)	2/10/1999 5:26:00 PM
From: poodle	Respond to of 804

Good evening, John. "From those over on the ENMD thread, I was hearing that that was going to be very tough to do. Looks like those guys were right." As you like to say, for the record... If my memory is correct, "those guys" at "early ENMD" board included 3 or 4 PhDs and post grad specialized in molecular biology and oncology, technician involved in protein preparation and couple of MDs. They analyzed majority of relevant scientific materials, protocols, and made necessary calculations. They were right? Probably, coincidence. Have a nice evening.